Galectin Therapeutics Inc
GALT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001133416
In the last 90 days, Galectin Therapeutics Inc insiders filed 0 open-market purchases and 1 sale; 98 institutions reported holding it in 13F filings for Q2 2026, worth $72.2M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Galectin Therapeutics Inc changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 79 | 94 | +15 |
| Shares | 9.75M | 10.1M | +345.2K (+3.5%) |
| Value | $26.8M | $13.0M | −$13.8M (−51.5%) |
New holders (21)
Institutions that held Galectin Therapeutics Inc at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sovran Advisors, LLC | 186,014 | $213.9K | 0.03% |
| Two Sigma Securities, LLC | 28,571 | $36.9K | 0.01% |
| HighTower Advisors, LLC | 22,486 | $29.0K | 0.00% |
| Gsa Capital Partners LLP | 21,534 | $28.0K | 0.00% |
| The PNC Financial Services Group, Inc. | 20,000 | $25.8K | 0.00% |
| HRT Financial LP | 19,543 | $25.0K | 0.00% |
| XTX Topco Ltd | 17,662 | $22.8K | 0.00% |
| Cahaba Wealth Management, Inc. | 17,000 | $21.9K | 0.00% |
| Engineers Gate Manager LP | 16,491 | $21.3K | 0.00% |
| SG Americas Securities, LLC | 13,935 | $18.0K | 0.00% |
| Argyle Capital Partners, LLC | 13,375 | $17.3K | 0.01% |
| Scientech Research LLC | 13,346 | $17.2K | 0.00% |
| Qube Research & Technologies Ltd | 12,130 | $15.6K | 0.00% |
| Raymond James Financial Inc | 11,550 | $14.9K | 0.00% |
| Financial Gravity Companies, Inc. | 5,997 | $7.74K | 0.00% |
| Caption Management, LLC | 5,475 | $7.06K | 0.00% |
| MAI Capital Management | 1,000 | $1.29K | 0.00% |
| Bradley & Co. Private Wealth Management, LLC | 1,000 | $1.29K | 0.00% |
| Ikarian Capital, LLC | 100 | $129 | 0.00% |
| EverSource Wealth Advisors, LLC | 46 | $59 | 0.00% |
| SBI Securities Co., Ltd. | 5 | $6 | 0.00% |
Sold out (6)
Institutions that held Galectin Therapeutics Inc at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Marshall Wace, LLP | 52,259 | $143.7K |
| ExodusPoint Capital Management, LP | 29,552 | $81.0K |
| Squarepoint Ops LLC | 27,435 | $75.4K |
| Summit Trail Advisors, LLC | 20,000 | $55.0K |
| Man Group plc | 12,654 | $34.8K |
| Russell Investments Group, Ltd. | 740 | $2.04K |